Thar Pharmaceuticals, which is developing oral therapies for complex regional pain syndrome, filed on Friday with the SEC to raise up to $50 million in an initial public offering.
The Pittsburgh, PA-based company was founded in 2006 and plans to list on the Nasdaq under the symbol THAR. SunTrust Robinson Humphrey is the sole bookrunner on the deal. No pricing terms were disclosed.
